Nothing new here I think. And nothing specific regarding progress monetising oncology assets:
"Bionomics has an ongoing process to monetise its oncology programs through divestment and/or out-licensing both BNC101 and BNC105 as the company completes its transition to a focused Central Nervous System (CNS) disorders company."
BNC 210 RESTORE results expected late this quarter. Very close now. Fingers crossed.
BNO Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
